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Abstract 
 
C-reactive protein (CRP) is a commonly used marker of systemic inflammation, 
routinely measured in serum blood samples. However salivary samples offer a non-
invasive and easily accessible alternative which would improve point of care (POC) 
testing for inflammation. Two major challenges restrict the use of saliva: the influence 
of the oral environment on CRP and its local production; and collecting a standardised 
sample given patient-dependent salivary flow rates. Here we review the reported 
studies of salivary CRP in humans as a potential marker of systemic inflammation and 
how the challenges can be overcome. Salivary CRP currently poorly reflects systemic 
inflammation as it does not consistently and strongly correlate with serum CRP. The 
mean and one standard deviation reported R2 values are 0.53  0.23 from 14 studies.  
An improved understanding of the key challenges and implemented solutions are 
needed to optimise salivary CRP use. Firstly, control for the effects of local oral 
inflammation. Screening for oral trauma is one option, however this could drastically 
limit the number of patients suitable for salivary CRP testing and the number of 
professionals able to use the POC test. Secondly,  the role of a dilution biomarker is 
considered controlling for salivary flow rate which dilutes serum CRP by ~104; a 
variable and likely-patient specific factor. The ideal dilution biomarker should have 
many of the pharmacokinetic, sensitivity and specificity characteristics of CRP. The 
potential for positive acute phase protein serum amyloid A (SAA) and negative acute 
phase protein albumin is considered and the characteristics of any correction function 
discussed. Currently, however, there are no available strategies to make salivary CRP 








Serum is the preferred biofluid for biomarker measurements diagnosing and managing 
a range of pathologies including inflammation (1, 2). However, recent advances in 
proteomics have highlighted the diagnostic potential of other biofluids, such as the use 
of cerebral spinal fluid in diagnosing Parkinson’s disease and urine in investigating 
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stable angina (3-5). Saliva has received considerable attention as it has many 
advantages over blood plasma. For example, it can be collected via a simple, non-
invasive method which does not require specialist training or equipment and places 
the collector at reduced infection risk compared to blood plasma collection. This makes 
it more suitable for repeated sampling, collection from difficult patients and in non-
clinical settings (6-10). Overall, this could make saliva an ideal means of systemic 
inflammation testing at POC, which could greatly improve the management of many 
pathologies, particularly inflammation and scenarios where repeated sampling would 
be of value such as in post-operative recovery to allow early detection of a 
complication and early intervention. 
 
The potential benefits of saliva have resulted in increased research leading to some 
established clinical uses, for example, in assessing cortisol and immunoglobin A levels 
and screening for human immunodeficiency virus via a POC device (8, 11). 
Furthermore, many potential uses of saliva, such as in diagnosing breast cancer, 
autism, cardio fitness and body mass index are under investigation (12, 13). However, 
before saliva-based diagnostics can be routinely used, multiple obstacles need to be 
overcome. The three major challenges are: the influence of the oral environment on 
CRP, collecting a standardised sample and extracting biomarkers reproducibly from 
the complex saliva matrix (7, 11, 14-16). Overcoming these challenges may enable 
saliva to be fully utilised, dramatically improving the ability to diagnose and manage 
pathologies. 
 
2.1. Saliva  
 
Saliva is a complex biofluid located within the oral cavity which may reflect systemic 
health (17). It is comprised of many components including salivary exocrine 
secretions, gingival crevicular fluid (GCF) and microbes (10, 18, 19). GCF is a serum 
exudate that carries all of the major components of the blood including Complement 
proteins, immunoglobins, cells such neutrophils and plasma cells and the acute phase 
proteins such as CRP and Serum Amyloid A (20, 21) Salivary exocrine secretions 
make up the majority of oral fluid and are primarily secreted by the parotid, submental 
and submandibular salivary glands (18). Salivary secretions include water, mucus and 
analytes such as immunoglobins and cortisol, which serve many functions for example 
in aiding digestion and taste (6, 18, 22, 23). Whilst GCF may reflect the blood plasma 
composition, the additional secretions from the three salivary glands dominate the 
plasma composition in two ways: 1) simple dilution; and 2) the saliva matrix may trap 
proteins which need to be recovered accurately prior to analysis. Consequently, the 
composition of the saliva may not reflect that of the plasma depending on the degree 
of salivation or simulated salivation during collection and the location in the mouth: 
small sample volume may show region specific concentrations.  Characterisation of 
the salivary proteome has highlighted that saliva is a promising biofluid with potentially 
multiple clinical uses, by detecting numerous serum biomarkers within saliva such as 
CRP and transferrin reflecting the blood proteome and the systemic acute phase 




Figure 1 – Relative abundance of 50 different proteins located within the saliva of 
healthy subjects. Relative prevalence is represented on a log scale, which spans 14 
orders of magnitude is represented on the abscissa. Gel-based and non-gel based 
proteomic technologies were utilised to calculate the relative abundance of the 
proteins (5). (Image reproduced with permission from the rights owner) 
 
2.2. Inflammation and CRP 
 
CRP is a key marker of inflammation within clinical practice. It is a pentameric 125.5 
kD positive acute phase protein (APP) that mediates innate immunity by bonding to 
foreign pathogens and damaged cells, triggering the Classical Pathway of the 
Complement cascade. It consists of 5 subunits each with a molecular weight of 25.106 
kD (15, 24-26). Intact CRP has a mass above the cut-off limit for renal excretion (43 
kDa)  and is a circulating biomarker of inflammation (27). CRP has been observed in 
the urine, especially during renal failure where the cut-off may be compromised. It is 
important to not however that all immune-assays formally the assay detection epitope 
which if present on the monomer, would not imply a degradation of the filtration cut-
off. Most manufacturers are not clear about the location of the detection epitope in a 
detection assay and the reported studies are unclear on the location of the epitope in 
theirs assays. 
 
Upon production, serum CRP levels rise up to 50,000-fold from baseline, doubling 
every 8 hours and peaking approximately 42 hours after the initial stimulus (1, 2). 
Alternative stimuli result in different CRP responses. For example, viral infections or 
mild inflammation causes serum levels between 10-40 mg/L, whereas severe bacterial 
infections and major trauma cause serum CRP levels to be greater than 300 mg/L 
(28). As serum CRP remains in the circulation and has a predictable response to 
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inflammatory stimuli it is the most commonly used clinical method for assessing 




Considerable research has been performed into whether salivary CRP has clinical 
potential. Investigations focus on whether salivary CRP levels correlate with its serum 
counterpart and the presence of pathologies. However, no review has focussed on the 
evidence to determine whether salivary CRP could be good marker of systemic 
inflammation and how salivary limitations may be overcome (6, 22, 29-39). This review 
aims to determine whether salivary CRP is a good biomarker of systemic inflammation. 
It critically analyses the detected correlations between serum and salivary CRP 
reported to date and the major challenges restricting the use of salivary CRP of the 
influence of the oral environment on CRP and collecting a standardised sample. 
Developing our understanding of these challenges may highlight solutions and guide 
further research which could make salivary CRP a better marker of systemic 
inflammation. Solving these challenges is essential if salivary CRP is to become a 
good marker of systemic inflammation, which could revolutionise the management of 
inflammation.  
 
3. CRP Presence within Saliva and Correlation with Serum CRP 
 
To determine if salivary CRP is a viable biomarker of systemic inflammation, a 
correlation between salivary and serum CRP levels needs to be established. The 
correlation would ideally be linear but could be of any order although non-linear 
correlations would be difficult to identify accurately. Arguably a pure GCF sample 
would show the highest correlation with serum levels with no reported mRNA for CRP 
production locally; the correlation degrading with the presence of other secretions and 
local inflammation recruiting CRP or potentially non-hepatic synthesis (21, 40). 
However, collection of GCF samples is considerably more difficult, requiring specialist 
training and equipment, limiting the suitability of this investigation tool. 
 
Multiple studies have assessed the correlation between salivary and serum CRP 
levels; fourteen studies are shown in Table 1 where the correlation has been reported 
explicitly or could be derived from the data. The studies varied considerably in their 
methodology, specifically whether they analysed the salivary-serum relationship in 
healthy participants, or subjects with varying sources and levels of inflammation. Most 
detected a positive correlation, however three studies found no correlation. 
Furthermore, the correlation coefficient strength varied considerably between and 
within studies (6, 22, 29-36, 38, 39, 41). For example, the highest correlation of 0.86 
was found between the salivary and serum CRP of hospitalised COPD patients. 
However, the control group had a lower correlation of 0.62 (30). Despite 
inconsistencies, overall the literature indicates a moderate correlation between 
salivary and serum CRP and a serum dilution factor of order 104 (6, 22, 29-36, 38, 39, 
41). The mean and standard deviation R2  values are 0.53  0.23; a 95% confidence 
limit on R2 is 0.07 – 0.99 – the correlation is not well established.   
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Table 1 Correlation coefficients from the selected studies identifying the cohort, size, 
the mean saliva and serum CRP concentrations and the saliva/serum ratio – the 




R2 = 0.84 
N = 28 Cardiac Patients N = 55 healthy patients;  
Paired serum-saliva CRP samples 
Mean Serum = 33 mg/L 
Mean Saliva = 285 pg/mL (healthy), 1680 
(cardiac) pg/mL 





R2 = 0.289 
R2 = 0.249 
N = 28, Acute MI patients, N = 28 Healthy 
Controls 
Mean Serum CRP healthy individuals (3.84 ± 
0.60) mg/L  
 
Mean Saliva 0.8 ng/mL (unstimulated) 
Mean Saliva 0.3 ng/mL (stimulated)  
Serum/Saliva ratio = 4.81103 (unstimulated) 
Serum/Saiva ration = 1.2 1104 (stimulated) 
(29) 





R2 = 0.62 
N = 100 COPD Patient cohort 
Mean Serum CRP = 90 g/mL 
Mean Saliva = 10.7 ± 4.8 g/mL 
Serum/Saliva ratio = 9 
 
N = 100 Control cohort 
Mean Serum mean = 0.45 ± 0.72 g/L  
Mean Saliva CRP 0.74 g/L 
Serum/Saliva ratio = 0.6  
(30) 
R2 =0.01 
N = 55 Healthy Adults 
Median Serum (plasma) CRP = 2.0 mg/L 
Median Saliva CRP  1.2 g/L 
Serum/Saliva ratio = 1.7 103 
(31) 
R2 =0.424 
(R2 =0.599 for 
high CRP) 
N = 18 Healthy Adults  
Mean Serum CRP = 2.24 104  ng/L 
Mean Saliva CRP = 0.08 ng/mL 
Serum/Saliva ratio = 2.8 105 
(32) 
R2 = 0.20 – 0.70 
N= 73 – 122  healthy adults and at risk of 
cardiovascular disease longitudinal study 
Mean plasma CRP 3.5  – 4.3 mg/L (over the time 
course) 
Mean saliva CRP 0.0026 – 0.0063 mg/L (over 
the time course) 
Serum/Saliva ratio = 1346 – 682 
(33) 
R2 = 0.424 – 
0.599 
 
N = 35, 17 depressed adolescents and 18 
healthy controls 
Mean plasma CRP 2.24 104 ng/mL 
Mean salivary CRP 0.08 ng/mL 
(34) 
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Serum/Saliva ration = 2.8106 
R2 = 0.66 
N=781  Post-menopausal women  
Mean Serum = 2908 ng/mL 
Mean Saliva = 0.992 ng/mL 
Saliva/serum = 2.9103 
(35) 
R2 = 0.73 
N=259, arterial stiffness and subclinical 
atherosclerosis 
Mean Serum 1.05 mg/L 
Mean Saliva 0.21 ng/mL 
Serum/Saliva ratio = 5103  
(36) 
R2 = 0.62 
N=40 neonates 
Mean Serum = 106 g/mL 
Mean Saliva = 3.1 ng/mL 
Serum/saliva = 3.4104   
(38) 
R = 0.41 
n = 61 healthy adults 
Mean serum = 2.02 mg/L 
Mean saliva = 2994 pg/mL 
Saliva/Serum 1633 
Note R2 value is re-derived from the Figure 1 in 
the reference which report a Pearson correlation 
coefficient r = 0.72. 
(39) 
R2 = 0.66 – 0.8 
N = 21 alcohol septal ablation and n = 97 healthy 
adult controls 
Longitudinal study 
Mean Serum = 50000 – 100000 ng/mL 
(estimated) 
Mean Saliva = 5 – 10 ng/mL (estimated) 
Saliva/Serum = 104  
(41) 
Mean R2 = 0.53  
0.23 
Mean of values or mid-range values with one 
standard deviation  
 
 
Correlation strength also varied depending on the serum CRP level. Four studies 
found that the salivary-serum CRP correlation was greater when serum levels were 
elevated (30, 34, 36, 39) probably due to relatively higher percentages changes in 
dilution. Understanding the causes of the correlation and dilution variances in the 
studies is important to determine if and how the salivary-serum CRP correlation can 
be improved, to achieve consistent correlations of 0.7 which is considered by some to 
be a strong correlation (42). From here, the coefficient of variation can be calculated. 
A coefficient of variation below 20% indicates that salivary CRP would be a suitable 
replacement for serum CRP (43). To strengthen the salivary-serum CRP correlation 
and enable salivary CRP to become a better marker of systemic inflammation, four 
key challenges need to be overcome. 
 
4. Challenge One – The Influence of the Oral Environment on CRP  
 
The local environment perturbs salivary CRP as a reflection of systemic inflammation 
with mechanisms local inflammation sites  and differential CRP clearance half-life (6, 
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22, 31, 32, 44, 45). Consequently, understanding and overcoming these limiting 
factors might improve the use of salivary CRP as a marker of systemic inflammation.  
 
4.1. Salivary CRP Half-life  
 
The half-life of salivary CRP is yet to be determined and must be different to the stable 
and well categorized half-life of serum CRP of 19 hours associated with hepatic 
clearance (1, 2). The environment within the oral cavity is highly variable and differs 
significantly from blood plasma. For example, the oral cavity is more alkaline and may 
contain many contaminants such as bacteria, food products and degraded proteins 
(22, 45). It is therefore highly likely that salivary CRP is not as stable and does not 
share the same half-life as serum CRP. Mirzaii-Dizgah et al. produced findings in 
myocardial infarction patients which indicated a reduced half-life of salivary CRP as 
levels began to return to baseline prior to serum levels. However, they did not 
determine the exact half-life of salivary CRP and only used two collection points over 
a 24-hour period to compare the time taken for salivary and serum CRP levels to return 
to baseline (29). Therefore, to confirm this trend and allow comparison with the half-
life of serum CRP, salivary and serum CRP levels need to be measured at more 
frequent time intervals.  
 
4.2. Impact of Local Inflammation  
 
The presence of inflammatory stimuli within the oral cavity may result in salivary CRP 
levels which are unrelated to the degree of systemic inflammation present. Localised 
inflammation could result in recruitment to the oral cavity, increased GCF secretion 
rates and the risk of bleeding into the saliva (46, 47). In the three studies which did not 
find a significant salivary-serum CRP correlation, the lack of control for oral health may 
have caused salivary-serum CRP levels to be unrelated (6, 31, 32). However, other 
studies, that also did not control for oral health, found significant correlations (29, 36, 
38, 41). The difference between these groups of studies is that the three studies which 
found no correlation used only ,or predominantly, healthy volunteers (6, 29, 31, 32, 
36, 38, 41). Two recruited only healthy volunteers and the third had over double the 
number of control participants compared to subjects with suspected pulmonary 
tuberculosis (6, 31, 32). As there was a significantly greater number of controls, the 
healthy population would have had a larger bias on the salivary-serum CRP 
correlation. Therefore, localised inflammation may only influence the salivary-serum 
CRP relationship in the absence or limited presence of systemic inflammation. If 
localised inflammation produces inaccurate results, the clinical utility of salivary CRP 
may be systematically limited due to the production of falsely high results. 
 
Significant levels of systemic inflammation could dominate the local oral cavity 
production. Redman et al., found that salivary and serum CRP levels remained 
correlated in rheumatoid arthritis or osteoarthritis sufferers who had periodontitis, a 
chronic inflammatory disorder of the gums that increases salivary CRP levels (16, 48, 
49). They concluded that CRP elevations induced by periodontitis were overshadowed 
by the presence of pathologies such as rheumatoid arthritis or osteoarthritis inducing 
inflammation (49). The impact of local inflammation on salivary CRP needs 
clarification in both healthy participants and subjects with elevated serum CRP to 
validate the need for control of oral trauma within the literature. 
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Understanding the influence of oral inflammation is important as it is a common 
comorbidity. One study, performed in the US between 2009 and 2010, found that 47% 
of the population suffered from periodontitis, most of which was of moderate severity 
(50). Furthermore, hospitalised patients have been found to have worse oral health 
when compared to outpatients. This could be the result of a higher likelihood of 
hospitalised patients having other comorbidities and medications which may alter the 
environment within the oral cavity (51). These factors are important as this cohort is 
more likely to warrant salivary CRP testing. Consequently, if the presence of localised 
inflammation means that salivary CRP testing is unsuitable, this severely limits the 
clinical utility of salivary CRP as a large cohort of subjects would be unsuitable for this 
investigation procedure. 
 
However, not all causes of localised inflammation may elevate salivary CRP levels. 
Gingivitis, inflammation of the gingival tissue which may progress into periodontitis, 
has been confirmed to have limited effect on salivary CRP levels in two studies (16, 
52). However, these studies used small cohort sizes and one found an insignificant 
elevation which may have become significant with a larger cohort (16, 52). Developing 
our understanding of how different types of localised inflammation influence the 
salivary-serum CRP relationship is essential. It may be that subjects with certain types 
or degrees of localised inflammation are suitable for this investigation, increasing 
salivary CRPs diagnostic utility. Further studies are required to understand if any 
localised inflammation disproportionately influences salivary CRP levels by 
recruitment, local production or bleeding, this would make salivary CRP a poor marker 
of systemic inflammation. 
 
4.3. Screening for Localised Trauma and Inflammation 
 
One solution to limit the influence of localised trauma on salivary CRP levels is to 
screen for oral inflammation. A range of different screening methods is currently in 
use. For example, one study used a brief questionnaire to assess oral health, whereas 
another performed clinical dental examinations including oral radiographs (33, 35). A 
dental examination is more representative than a self-reported questionnaire. 
However, a dental examination is considerably more specialist, time consuming and 
invasive to perform, which would dramatically reduce the practicality of salivary CRP 
testing and its attraction as a non-invasive measurement. Self-reporting 
questionnaires found a stronger salivary-serum CRP correlation, however, there may 
be confounding factors such as analysis technique (22, 35, 39). The development of 
a standardised, simple, quick and accurate method of screening for localised 
inflammation is essential for creating an investigative tool that maximises the benefits 
of salivary CRP and enables greater comparisons between studies.  
5. Challenge Two – Collecting a Standardised Sample 
 
In order to increase the ability of salivary CRP to monitor systemic inflammation, a 
consistent collection method that optimises salivary CRP levels is required. Currently, 
no consistent method is used and clearly reflects differential dilution in the oral cavity, 
a key challenge (22, 33-36, 38, 41, 53, 54). Many other areas require research and 
standardisation, such as the need to control for the level of stimulation, collection 
location and technique, however, until further research is performed these can all be 
controlled by applying consistent control methods (6, 19, 22, 29-39, 54-58).  
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5.1. Control of Salivary Flow Rate  
 
One key factor influencing saliva samples is effectively controlling the variable flow 
rate of saliva (59). Salivary flow rate is influenced by many variables including the level 
of stimulation present, pharmaceuticals and patient comorbidities such as diabetes 
(60, 61). Furthermore, there is considerable variability within healthy individuals. For 
example, one study of 25 healthy individuals between the ages of 20 and 35, found 
unstimulated flow rate to vary by almost 50% of the average flow rate (54).  
 
Despite the development of multiple methods to control for variable flow rate, none of 
these have yet provided a suitable solution. Controlling via total salivary volume has 
been used to normalise analyte levels in multiple studies. However, this method 
provides a weaker correlation with CRP levels than other methods (38). Furthermore, 
this method may be unsuitable for POC devices as it requires the collection of large 
quantities of saliva for assessment. Calculating salivary flow rate to normalise samples 
also suffers this same flaw as it requires large sample volumes collected over a 
prolonged time period (38). Moreover, three studies found that salivary CRP does not 
correlate with salivary flow rate, indicating that this control method is inadequate (31, 
39, 62). However, it may also highlight that it is not necessary to control for salivary 
flow rate. All three studies used healthy individuals and controlled for the level of 
stimulation present, which did not improve the correlation. It is possible that there may 
not have been enough variation to detect discernible differences in CRP levels for 
correlation (31, 39, 62). 
 
Measuring the total protein concentration alongside analyte levels provides a potential 
dilution control method and would be the comparatively straightforward to implement 
in a POC device and has been shown to improve the correlation (38). Total protein 
levels would also be vulnerable to the same problems associated with local trauma 
and variable levels of stimulation whereby the protein composition can vary 
significantly (63-65). Therefore, similar protein concentrations could have a very 
different protein composition, meaning that total protein concentration may not 
accurately reflect salivary CRP levels. 
 
5.2. Development of a Dilution Marker 
 
Dilution factors of order 1.6  104 have been reported coupled with the 50% variation 
of reported salivary flow rates,  demonstrates the magnitude of the dilution problem 
(39).  The mean correlation between salivary and serum CRP is R2 = 0.53  0.23 
(mean and standard deviation): small patient variations form day-to-day as well as 
patient to patient of the large dilution factor could degrade the correlation and its 
predictive value for serum CRP concentrations. There may be sufficient diagnostic 
value in identifying CRP-positive saliva but the ideal diagnostic value would be a 
quantitative measure of salivary CRP to predict serum CRP to invoke all of the 
diagnostic thresholds and trends that are well established in many disease states.  
 
One solution to overcome the variable salivary flow rate and patient variability in 
dilution could be simultaneous detection of another analyte or panel of analytes, 
alongside CRP, within samples that is known to be derived from the serum, 
referencing the CRP level to the systemic level – a dilution marker. A function of two 
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or more analytes dilution markers could be derived from which the serum 
concentration could be inferred quantitatively. There are a number of characteristics 
of a dilution marker or combinations of markers:  
  
1) the biomarker should be derived from the serum reflecting systemic 
inflammation; 
2) the biomarker should ideally remain constant for all levels of serum CRP in 
all pathophysiological conditions;  
3) if the biomarker concentration is not constant should have known 
fluctuations or definable variations strongly related to those of CRP under 
all pathophysiological conditions; 
4) the biomarker should have a similar rate of production and half-life to 
salivary CRP to follow faithfully the serum concentration;  
5) the biomarker should to enter the oral cavity by the same mechanism as 
CRP to control for the impact that the collection method and local trauma 
has upon the results; and  
6) any differential local confounding mouth-specific factors need to be 
detailed. 
 
These are severe constraints on the properties of any one dilution marker but a 
quantitative dilution marker strategy is more likely to reflect more accurately the serum 
CRP levels than a correlation coefficient or an average dilution factor correction. 
 
A first set of possible makers may be found in the APP, for example, Serum Amyloid 
A levels increase up to 1000-fold from baseline in 24-48 hours similar to CRP, whereas 
haptoglobin levels increase 3-fold over a period of 3 days; some properties of other 
APPs are shown in Table 2 (66, 67). APPs tor combinations therefore may be suitable 
dilution markers as they change in the presence of the same inflammatory stimuli as 
CRP and are, principally, synthesised de novo in the liver. The two extreme cases are 
SAA which behaves in a similar way to CRP rising rapidly during the acute phase 
response and albumin which is a negative acute phase protein, slow to respond and 
has a moderately low dynamic range. 
 








CRP Increase 48-72 hours 50,000% 
SAA Increase 48-72 hours 100,000% 
Haptoglobin Increase 72 hours 300% 
Alpha1-Acid Glycoprotein Increase 72 hours 150% 
Fibrinogen Increase 5 days 200% 
Alpha1-Antitrypsin Increase 5 days 200% 
Ceruloplasmin Increase 14 days 130% 
Immunoglobulin M Increase 30 days 130% 
Transferrin Decrease 3-7 days 10-80% 
Albumin Decrease 3-9 days 10-80% 




SAA may be a suitable dilution marker because of its similarities to CRP and relative 
ease to measure. However, significant uncertainties exist within its serum form (68), it 
is however relatively easy to measure. SAA is a family of apolipoproteins that transport 
phospholipids to damaged tissues. Phospholipids then assist in tissue regeneration 
and recruit inflammatory cells to the sites of inflammation (1, 66, 69). SAA responds 
to the same inflammatory stimuli, such as septic shock, myocardial infarctions and 
physical trauma in a similar fashion to CRP (66, 67, 70, 71). Specifically, CRP and 
SAA share co-stimulation by IL-6, large dynamic range, rapid response in the first 24h 
– 48h, a comparable time taken to reach maximum concentration, return to baseline 
and serum half-life (1, 66, 67, 72-76). Variations within these exist, for example SAA 
takes longer to return to baseline (1, 67, 73, 74). However, the differences appear to 
be small. 
 
Whilst it might be hoped that SAA tracks CRP closely, there is reasonable evidence 
to suggest there is differential response of SAA to CRP depending on the origin of the 
infection (73, 77). Furthermore, it is unclear if salivary SAA reflects serum levels, 
verified only in animal models (37, 78, 79). The only human study performed on 
salivary SAA detected no significant elevation in the presence of inflammation (80). 
Therefore, clarification over how human salivary SAA responds to systemic 
inflammation and relates to CRP is required. Finally, before SAA can be used as a 
dilution marker, there needs to be clarification over how it enters saliva and whether 
salivary SAA reflects serum levels. SAA is a lipophilic molecule of between 11.4 and 
12.5 kDa, therefore it may enter the oral cavity via active transport and transudation, 
which is different from CRP (60, 81, 82). Moreover, SAA may be produced locally as 
mRNA has been detected within human tonsillar tissue (83). Further confirmation of 
these entry methods is required as the presence of SAA within the oral cavity could 
be dependent on different factors to CRP. Consequently, whilst initially promising, 
SAA may not correlate with CRP or represent serum levels and would be an 
inadequate dilution marker on its own.  
 
SAA is a rapidly varying protein tracking CRP; the alternative is a protein with a smaller 
dynamic range or falling during infection such as albumin or transferrin. Albumin is one 
of the most abundant proteins found within human serum and functions in maintaining 
osmotic pressure and transporting proteins, such as fatty acids and steroids (4, 84, 
85). In the presence of some inflammatory stimuli, serum levels decline by between 
10% to 80% to allow for an increased production of positive APPs but over a period of 
3 – 9 days (1, 66, 86). However, a promising feature of salivary albumin, is that in the 
presence of systemic inflammation its levels remain unchanged (51, 61, 87, 88). This 
may be because salivary levels are much lower and therefore detecting significant 
differences is more challenging. A non-significant change could make salivary albumin 
exceptionally useful as the differences in the half-life, time taken to peak and return to 
baseline between CRP and albumin become unimportant, hence the albumin-CRP 
ratio would only be dependent on CRP levels (51, 66, 67). However, salivary albumin 
has several flaws restricting its use as a dilution marker. For example, it has a high 
degree of inter-patient variation in healthy individuals (89, 90). Salivary albumin levels 
are also elevated in the presence of oral inflammation, although the prevalence of 
such conditions in the population is unknown and may have an acceptable false-





Salivary CRP would have significant clinical value as a biomarker of systemic 
inflammation due to it being derived from a non-invasive biological sample. It could be 
measured simply at point-of-care and more frequently to provide trend information 
rather than absolute single-point measures. There are however significant challenges 
in recovering analytes reproducible from the complex matrix that is saliva and the 
mechanism by which molecules enter the saliva from the blood. Ideally, a simple 
correlation would allow the salivary CRP to be corrected to the serum CRP by a simple 
correlation but the current set of 12 studies, shows an average R2 of 0.53  0.23 (mean 
and standard deviation), see Table 1. However, some studies report levels of 
correlation as high as 0.86 which suggest the search for a reproducible measurement 
protocol could deliver the required correlation.  
 
6.1. Improving the Salivary CRP-Serum CRP Predictive Value 
 
The current observed variation in the correlation between serum and salivary CRP 
may be explained by (at least) two major factors: changes to the CRP concentration 
caused by localised inflammation in the mouth and difficulties in collecting a consistent 
saliva sample. Other factors include working with the saliva matrix separating the 
proteins reproducibly, the collection protocol, the mode of entry of the serum proteins 
into the saliva – is this active or passive and is there a cut-off. Most importantly if the 
non-invasive sampling is to be exploited, a point-of-care test to perform the analysis 
with a sufficient sensitivity to measure the very low concentrations of CRP, ~2 g/L.    
 
The impact of local trauma on CRP concentration is a significant challenge. A 
significant number of studies have evidenced the effect of trauma (6, 16, 29, 31, 32, 
36, 38, 41, 49, 52). This is important as if a successful control could not be found, the 
utility of salivary CRP testing would be limited to a small subset of the population. The 
obvious solution is a clinical examination using some form screening tool based on an 
examination and clinical judgement. The clinical screening tool would however be 
limited by a visual inspection which will not be sufficiently sensitive or specific to make 
an accurate, quantitative correction of the salivary CRP level.  Improving the sensitivity 
and specificity of the screening tool would mean an increase in complexity, could 
require specialist training, increasing cost, restricting collection to only trained 
personnel and defeating the utility of a low-burden biosample. This is the biggest 
limitation in the use of salivary CRP as a marker of systemic inflammation and 
therefore, needs prioritising in salivary CRP research. If it is found to be unsuitable 
due to the impracticalities of screening and the low percentage of patients who are 
suitable for the test, then further research to overcome the other challenges would be 
inappropriate. Fundamentally, a control measurement should be made simultaneously 
with the CRP to eliminate any inspection and localise the CRP concentration to the 
systemic blood.  
 
The second major challenge is developing a suitable method of controlling for the 
dilution of saliva. This may yield the greatest improvements in the salivary-serum CRP 
relationship as the dilution of saliva is highly variable and the current available 
methods to control it are ineffective and unsuitable for a POC device (38, 54, 60, 61). 
The use of a dilution marker may prove to be the most promising solution but the 
challenge is the quantitative accuracy of the correction. Ideally, a robust monotonic 
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(single-valued over the diagnostic range of CRP) correction should be made to allow 
the serum CRP diagnostic thresholds to be mapped to the salivary concentration. The 
APP themselves perhaps in combination are interesting as detailed for SAA and 
albumin but these come with problems that need to be understood. Measurement of 
several APPs could allow the effect of dilution as well as local inflammation to be 
addressed. A salivary correction function based on an acute phase signature would 
show the rise in the systemic inflammation with a local inflammation patterns 
superposed. A dilution biomarker panel could exploit the differential local inflammation 
effects of say SAA over CRP and provide a discrimination between local and systemic 
effects. The biomarker panel correction function is likely to be complex and non-linear 
and would need considerable validation.  
 
The patient variability in the dilution factor and any dilution biomarker is a considerable 
unknown. An inert protein biomarker such as IgD with no known clinical function or 
significant variation is an interesting target with a comparatively small concentration 
variation in the population (91). Similarly, albumin varies between 10% - 80% over a 
period of three days (1, 66, 86). The clinical question is whether these moderate 
changes affect the diagnostic accuracy of the CRP test or systemic inflammation 
biomarker and the outcome of a clinical intervention. Considerable research is 
required to validate a quantitative correction of salivary CRP to predict accurately the 
serum, systemic biomarker concentrations.  
 
If no correction function could be found of the evaluation time is significant then 
salivary CRP may still have several potential uses in detecting systemic inflammation 
as serum positive or negative. Quellet-Morin et al. and Out et al. both used salivary 
CRP levels to predict whether serum CRP levels exceeded a 3 mg/L cut-off to assess 
for cardiovascular disease. They produced results with sensitivities ranging from 66-
89%, which are promising as 89% is considered a good measure of discrimination (33, 
39). However, further research is required for using this cut-off to determine the tests 
specificities and true and false positive and negatives, which would be required for use 
in clinical practice. Lyengar et al. used salivary CRP to predict if serum levels 
exceeded alternative cut-offs of 5 and 10 mg/L with respective sensitivities and 
specificities of 64% and 94% for 5 mg/L and 54% and 95% for 10 mg/L (38). The 10 
mg/L cut-off is significant as CRP results at this value are clinically abnormal (92). 
Other clinically relevant cut-off points could also be used. For example, 40 mg/L 
distinguishes between a bacterial and viral source of inflammation, consequently this 
cut-off value may help differentiate these inflammatory stimuli (28). This would help to 
guide management and reduce the prescription of unnecessary antibiotics. The risk of 
using cut-offs when biomarkers are subject to differential dilution could lead to false 
negative results in screening.  
 
Salivary CRP could also be applied alongside other markers to produce a composite 
score that indicates the presence of pathologies. For example, Floriano et al. used 
salivary CRP, myeloperoxidase, myoglobin and an electrocardiogram to detect acute 
myocardial infarctions with a sensitivity and specificity of 93% and 86%. This 
compares favourably to serum screening methods, but requires confirmation in larger 
cohort sizes where the diagnoses are unknown (93). Nevertheless, despite further 
research being required, multiple potential uses of salivary CRP are available if a 
strong salivary-serum CRP relationship is not present.  
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Using salivary CRP to determine when serum CRP levels exceed cut-off points has 
clinical potential,. However, this use has significantly fewer applications and still 
requires considerable research, particularly in determining how localised trauma 
influences analyte levels and in developing a POC investigation tool. Therefore, the 
potential yield of research would be reduced, but if it can be used to accurately detect 
pathologies, then this may still provide a quick and accurate means of detecting 
systemic inflammation that is not currently possible. 
7. Conclusion 
 
Salivary CRP appears to be derived, presumably passively, from the serum, principally 
though the GCF as an exudate and then diluted ~104 in the mouth depending on 
stimulation, the patient response and critically on the collection protocol.  Only with 
these major challenges solved can salivary CRP be a good quantitative predictor of 
systemic inflammation. It is currently a poor quantitative biomarker of systemic 
inflammation as it does not consistently and strongly correlate with serum levels. The 
effects of local inflammation could be overcome with a screening tool but a complex 
tool would be required with high sensitivity and specify which would defeat the 
simplicity and utility of salivary sampling. Overcoming the variable dilution and local 
inflammation problems with a multiplexed biomarker panel could provide controls for 
both dilution and differential makers of local inflammation. Internal controls would 
recover the sampling simplicity but would require a significant validation process. In 
the interim a set of saliva positive – saliva negative tests may be nearer to clinical 
implementation of salivary testing. It would then need to compete effectively with urine 
analysis where similar problems of dilution, hydration and local vs system 
inflammation exist. The implementation of frequent systemic biomarker measurement 
in a non-invasive fluid remains attractive especially at point-of-care.   
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